Cargando…
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
Mantle cell lymphoma (MCL) is considered one of the most challenging lymphoma, with limited responses to current therapies. Acadesine, a nucleoside analogue has shown antitumoral effects in different preclinical cancer models as well as in a recent phase I/II clinical trial conducted in patients wit...
Autores principales: | Montraveta, Arnau, Xargay-Torrent, Sílvia, López-Guerra, Mónica, Rosich, Laia, Pérez-Galán, Patricia, Salaverria, Itziar, Beà, Silvia, Kalko, Susana G., de Frias, Mercè, Campàs, Clara, Roué, Gaël, Colomer, Dolors |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996675/ https://www.ncbi.nlm.nih.gov/pubmed/24519895 |
Ejemplares similares
-
Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015) -
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
por: Rosich, Laia, et al.
Publicado: (2014) -
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
por: Xargay-Torrent, Sílvia, et al.
Publicado: (2015) -
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015) -
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
por: Van Den Neste, Eric, et al.
Publicado: (2012)